Adiponectin actions in the cardiovascular system

被引:256
作者
Hopkins, Teresa A. [1 ]
Ouchi, Noriyuki [1 ]
Shibata, Rei [1 ]
Walsh, Kenneth [1 ]
机构
[1] Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA
关键词
diabetes; epidemiology; heart failure; remodeling; protein kinases;
D O I
10.1016/j.cardiores.2006.10.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Obesity is strongly associated with the pathogenesis of type 2 diabetes, hypertension, and cardiovascular disease. Levels of the hormone adiponectin are downregulated in obese individuals, and several experimental studies show that adiponectin protects against the development of various obesity-related metabolic and cardiovascular diseases. Adiponectin exhibits favorable effects on atherogenesis, endothelial function, and vascular remodeling by modulation of signaling cascades in cells of the vasculature. More recent findings have shown that adiponectin directly affects signaling in cardiac cells and is beneficial in the setting of pathological cardiac remodeling and acute cardiac injury. Several of these effects of adiponectin have been attributed to the activation of the 5' AMP-activated protein kinase signaling cascade and other signaling proteins. This review will discuss the epidemiological and experimental studies that have elucidated the role of adiponectin in a variety of cardiovascular diseases. (c) 2006 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:11 / 18
页数:8
相关论文
共 107 条
[91]   Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications [J].
Waltenberger, J .
CARDIOVASCULAR RESEARCH, 2001, 49 (03) :554-560
[92]   Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner [J].
Wang, Y ;
Lam, KSL ;
Xu, JY ;
Lu, G ;
Xu, LY ;
Cooper, GJS ;
Xu, AM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (18) :18341-18347
[93]   Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia [J].
Weyer, C ;
Funahashi, T ;
Tanaka, S ;
Hotta, K ;
Matsuzawa, Y ;
Pratley, RE ;
Tataranni, PA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (05) :1930-1935
[94]   Body mass index - A risk factor for unstable angina and myocardial infarction in patients with angiographically confirmed coronary artery disease [J].
Wolk, R ;
Berger, P ;
Lennon, RJ ;
Brilakis, ES ;
Somers, VK .
CIRCULATION, 2003, 108 (18) :2206-2211
[95]   Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes [J].
Wu, XD ;
Motoshima, H ;
Mahadev, K ;
Stalker, TJ ;
Scalia, R ;
Goldstein, BJ .
DIABETES, 2003, 52 (06) :1355-1363
[96]   Adiponectin differentially regulates cytokines in porcine macrophages [J].
Wulster-Radcliffe, MC ;
Ajuwon, KM ;
Wang, JZ ;
Christian, JA ;
Spurlock, ME .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 316 (03) :924-929
[97]   Prostaglandin E2 protects the heart from ischemia-reperfusion injury via its receptor subtype EP4 [J].
Xiao, CY ;
Yuhki, K ;
Hara, A ;
Fujino, T ;
Kuriyama, S ;
Yamada, T ;
Takayama, K ;
Takahata, O ;
Karibe, H ;
Taniguchi, T ;
Narumiya, S ;
Ushikubi, F .
CIRCULATION, 2004, 109 (20) :2462-2468
[98]   Roles of prostaglandin I2 and thromboxane A2 in cardiac ischemia-reperfusion injury -: A study using mice lacking their respective receptors [J].
Xiao, CY ;
Hara, A ;
Yuhki, K ;
Fujino, T ;
Ma, H ;
Okada, Y ;
Takahata, O ;
Yamada, T ;
Murata, T ;
Narumiya, S ;
Ushikubi, F .
CIRCULATION, 2001, 104 (18) :2210-2215
[99]   Adiponectin inhibits Toll-like receptor family-induced signaling [J].
Yamaguchi, N ;
Guillermo, J ;
Argueta, M ;
Masuhiro, Y ;
Kagishita, M ;
Nonaka, K ;
Saito, T ;
Hanazawa, S ;
Yamashita, Y .
FEBS LETTERS, 2005, 579 (30) :6821-6826
[100]   Adiponectin, an adipocyte-derived protein, predicts future insulin resistance: Two-year follow-up study in Japanese population [J].
Yamamoto, Y ;
Hirose, H ;
Saito, I ;
Nishikai, K ;
Saruta, T .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (01) :87-90